PE4S217 - Personalised Weight Management (2): Medical Treatments and Emerging Therapies 01 Sep 2021 - 31 Aug 2027 | Version 1

Associated Module Information

Module Code: PE4S217
Module Title: Personalised Weight Management (2): Medical Treatments and Emerging Therapies
Faculty: Faculty of Life Sciences and Education
Faculty Group: Allied Health and Chiropractic
Faculty Sub Group: Clinical Services
Module Leader: Karl New
Module Team:
First Intended Intake: SEP 2021 Final Year of Intake:
Date Closed:
Credit Value: 20 Credit Level: 7
Language: English
Percentage of Module Taught in Welsh: 0
Equivalent Module:
HECOS codes: 100260 - healthcare science
HECOS Code Weighting: 100

Document Version Information

Version 1
Valid From 01 Sep 2021
Valid To 31 Aug 2027

Module Aims

To enhance the knowledge and clinical skills required to effectively evaluate and treat obesity with emphasis on personalised care, pharmacotherapy and new and emerging therapies.

Content Summary

• Analysis of specific guidelines for obesity pharmacotherapy.
• The role and clinical applicability of medical therapies in weight management.
• The pharmacological effects, mechanism of action, efficacy and adverse events associated with licensed medical therapies used in weight management and evaluation of the evidence.
• Unlicensed therapies used in weight management, their pharmacological properties, evidence regarding their use, controversies and legalities of use, and the associated adverse effects.
• Previously licensed/used medical therapies, their pharmacology and reasons for withdrawal with an emphasis upon pharmacovigilance and post marketing surveillance.
• The role of emerging therapies in weight management with emphasis upon the physiological basis for potential therapies.

Learning and Teaching Methods

Activity Type Hours
Independent Study 100
Directed Study 100
Total Hours Selected 200

Learning Outcomes

# Learning Outcome
LO1 Demonstrate a critical understanding of medical therapies used in the clinical treatment of obesity and application of this understanding to the personalised care of the person living with obesity
LO2 Demonstrate a critical understanding of past, current, new and emerging therapies for weight management and the role of pharmacovigilance in evaluating their adverse effects.

Module Requisites

N/A

Assessment Criteria

Assessment Category Assessment Type Description Duration Word Count Weight (%) Best of? Pass Mark
Synchronous Online Assessment Time-constrained assessment (Online) 1 End of Module examination related to personalised weight management using medical treatments and emerging therapies 60 N/A 30 No 40
Asynchronous Assessment Self Reflective Assessment 1 Reflective Journal 0 600 10 No 40
Asynchronous Assessment Project 1 Completion of a group task related to personalised weight management using medical treatments and emerging therapies 0 N/A 20 No 40
Asynchronous Assessment Case study 1 Case based scenarios and discussion forum related to personalised weight management using medical treatments and emerging therapies 0 N/A 40 No 40

Assessment Matrix

Assessment Type Learning Outcomes
LO1 LO2
Time-constrained assessment (Online) 1
Self Reflective Assessment 1
Project 1
Case study 1

Reading List

National Institute for Health and Care Excellence (NICE). Obesity: identification, assessment and management of overweight and obesity in children, young people and adults. (2014) Available at http://www.nice.org.uk/guidance/cg189/resources/guidance-obesity-identification-assessment-and-management-of-overweight-and-obesity-in-children-young-people-and-adults-pdf

Bray, G., Bouchard, C. (2014) Handbook of Obesity (Two-volume set) : CRC Press

Tackling the obesity pandemic. Latest Scientific Insights and novel clinical strategies. Medscape March 2015 http://www.medscape.org/viewarticle/837674?src=wnl_cme_revw&impID=659610

Alamuddin, N., Bakizada, Z. and Wadden, T. A. (2016) ‘Management of obesity’, Journal of Clinical Oncology, 34(35), pp. 4295–4305. doi: 10.1200/JCO.2016.66.8806.

Bray, G.A., Frühbeck, G., Ryan, D.H. and Wilding, J.P., (2016). Management of obesity. The Lancet, 387(10031), pp.1947-1956.

Caveney, E., Caveney, B.J., Somaratne, R., Turner, J.R. and Gourgiotis, L., (2011). Pharmaceutical interventions for obesity: a public health perspective. Diabetes, Obesity and Metabolism, 13(6), pp.490-497.

Wharton, S., Lau, D.C., Vallis, M., Sharma, A.M., Biertho, L., Campbell-Scherer, D., Adamo, K., Alberga, A., Bell, R., Boulé, N. and Boyling, E., (2020). Obesity in adults: a clinical practice guideline. CMAJ, 192(31), pp.E875-E891.

Yumuk, V., Tsigos, C., Fried, M., Schindler, K., Busetto, L., Micic, D. and Toplak, H., (2015). Obesity Management Task Force of the European Association for the Study of, O. European Guidelines for Obesity Management in Adults. Obes. Facts, 8, pp.402-424.